In cisplatin-resistant ovarian cancer cells, JAK/STAT3 signaling is hyperactive, with enhanced cell colony-forming capacity and metastasis capacity, which can be reduced by STAT3 inhibitors (Xia et al., 2022). The gene discussed is STAT3; the disease is ovarian carcinoma.